ROVI announces the agreement with Sandoz to distribute and market its Enoxaparin biosimilar


No votes yet
 
Related
Laboratorios Farmacéuticos Rovi, S.A. (www.rovi.es) today announced topline results from the pivotal study PRISMA-3, a multicenter,...
4 min
19/03/2019
The operating revenue of Laboratorios Farmacéuticos ROVI increased by 10% to 303.2 million euros in 2018, driven mainly by the strength of...
5 min
26/02/2019